SAN DIEGO, April 11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, today announced that Evan M. Levine,
chief executive officer, will present a corporate overview at the 7th
Annual Fortis Biotech Conference on April 25 at 1.45 p.m. British Summer
Time (8:45 a.m. Eastern Daylight Time). The conference is being held at the
Four Seasons Hotel, Park Lane, London.
A link to the live webcast of the presentation can be accessed via the
"Investors" section of the Company's corporate web site at
http://www.adventrx.com under "Events." The webcast will be made available
for replay for 14 days and can be accessed through the same link.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. The Company's lead product
candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b clinical trials
for the treatment of metastatic colorectal cancer, as well as in a Phase 2
clinical trial for the treatment of advanced breast cancer. More
information can be found on the Company's web site at
http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The potential
risks and uncertainties that could cause actual results to differ
materially include, but are not limited to: uncertainties inherent in the
drug development process; the timing and success of clinical trials; the
validity of research results; the receipt of necessary approvals from the
FDA and other regulatory agencies; and other risks and uncertainties more
fully described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at http://www.sec.gov. ADVENTRX
does not intend to update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances arising
after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/gh/cnoc/comp/920134.html/
CONTACT:
Media, Amy Martini of WeissComm Partners,
+1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc.; or
Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866
|
